Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Kate Geschwind"'
Autor:
Kristin L. M. Boylan, Kate Geschwind, Joseph S. Koopmeiners, Melissa A. Geller, Timothy K. Starr, Amy P. N. Skubitz
Publikováno v:
Clinical Proteomics, Vol 14, Iss 1, Pp 1-21 (2017)
Abstract Background Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovaria
Externí odkaz:
https://doaj.org/article/1add60ae1fbf46658bf4960d9820087b
Autor:
Joseph S. Koopmeiners, Karen H. Lu, Robert C. Bast, Joseph Celestino, Melissa A. Geller, Timothy K. Starr, Qing Cao, Kate Geschwind, Kristin L.M. Boylan, Amy P.N. Skubitz
Supplemental Table S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0483eb3fdfe4b43ec177afdfbae99728
https://doi.org/10.1158/1940-6207.22534201
https://doi.org/10.1158/1940-6207.22534201
Autor:
Joseph S. Koopmeiners, Karen H. Lu, Robert C. Bast, Joseph Celestino, Melissa A. Geller, Timothy K. Starr, Qing Cao, Kate Geschwind, Kristin L.M. Boylan, Amy P.N. Skubitz
Animation of PCA for Figure 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0e56141c775e4e0ce24ecb6ecf4076
https://doi.org/10.1158/1940-6207.22534207.v1
https://doi.org/10.1158/1940-6207.22534207.v1
Autor:
Joseph S. Koopmeiners, Karen H. Lu, Robert C. Bast, Joseph Celestino, Melissa A. Geller, Timothy K. Starr, Qing Cao, Kate Geschwind, Kristin L.M. Boylan, Amy P.N. Skubitz
The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccc7e61d686e6173f7242a856d0c99ea
https://doi.org/10.1158/1940-6207.c.6547402.v1
https://doi.org/10.1158/1940-6207.c.6547402.v1
Autor:
Kate Geschwind, David V. Power
Publikováno v:
Evidence-Based Practice. 25:36-37
Autor:
Kate Geschwind, Melissa A. Geller, Kristin L.M. Boylan, Amy P.N. Skubitz, Timothy K. Starr, Joseph S. Koopmeiners
Publikováno v:
Clinical Proteomics, Vol 14, Iss 1, Pp 1-21 (2017)
Clinical Proteomics
Clinical Proteomics
Background Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer
Autor:
Qing Cao, Kristin L.M. Boylan, Amy P.N. Skubitz, Karen H. Lu, Joseph Celestino, Ashley Petersen, Robert C. Bast, Timothy K. Starr, Xuan Pu, Kate Geschwind
Publikováno v:
Clinical Cancer Research. 26:B43-B43
The two bes- known ovarian cancer biomarkers, CA125 and HE4, are neither adequately sensitive nor specific to be used to screen the general population for early stages of ovarian cancer. The purpose of this study was to develop a multiprotein classif
Autor:
Joseph Celestino, Qing Cao, Melissa A. Geller, Joseph S. Koopmeiners, Timothy K. Starr, Karen H. Lu, Kristin L.M. Boylan, Amy P.N. Skubitz, Robert C. Bast, Kate Geschwind
Publikováno v:
Clinical Cancer Research. 25:AP08-AP08
There are no FDA approved screening tools for detecting ovarian cancer in the general population. The two best known ovarian cancer biomarkers, CA125 and HE4, are neither adequately sensitive nor specific when used alone to screen the general populat
Autor:
Kristin L.M. Boylan, Amy P.N. Skubitz, Melissa A. Geller, Timothy K. Starr, Karen H. Lu, Joseph Celestino, Joseph S. Koopmeiners, Qing Cao, Robert C. Bast, Kate Geschwind
Publikováno v:
Cancer prevention research (Philadelphia, Pa.). 12(3)
The best known ovarian cancer biomarker, CA125, is neither adequately sensitive nor specific for screening the general population. By using a combination of proteins for screening, it may be possible to increase the sensitivity and specificity over C
Publikováno v:
Journal of Translational Medicine
Background Adjuvant imatinib is useful in patients with gastrointestinal stromal tumors (GIST) at high risk of recurrence. At present, the risk of recurrence is determined based on tumor size, mitotic rate, tumor site, and tumor rupture. Previous stu